KORU Medical Systems’ FreedomEdge Infusion System Clears Regulatory Hurdles in Japan, Expanding Accessibility for Multiple Drug Delivery
Mahwah, N.J. - KORU Medical Systems, Inc. (NASDAQ: KRMD), a leading medical technology company dedicated to developing, manufacturing, and commercializing innovative large volume subcutaneous infusion solutions, has recently achieved a significant breakthrough. The state-of-the-art FreedomEdge System has received regulatory clearance in Japan for the delivery of multiple drugs, including CSL Behring’s Hizentra subcutaneous immunoglobulin (SCIg). This achievement not only strengthens KORU Medical’s global presence but also expands accessibility to life-enhancing treatments for patients in need.
The Japanese regulatory clearance for the FreedomEdge System is a testament to its advanced capabilities and promising future in the medical field. The innovative system allows for the efficient delivery of multiple drugs, offering healthcare professionals and patients flexibility and convenience in disease management. KORU Medical’s commitment to patient-centric care is further exemplified through its efforts to collaborate with pharmaceutical companies, such as CSL Behring, to bring essential treatments to the market.
CSL Behring’s Hizentra, a subcutaneous immunoglobulin therapy, is a crucial treatment option for patients with primary immunodeficiency diseases (PI). By incorporating it into the FreedomEdge System, KORU Medical empowers Japanese patients living with PI to conveniently administer their therapy at home, thus reducing the burden of hospital visits and enhancing their overall quality of life.
In addition to this achievement, KORU Medical has recently signed a Phase III clinical supply agreement for a novel enzyme replacement therapy. This treatment aims to combat a rare endocrinological disease, representing a significant milestone in the company’s mission to develop innovative solutions for complex medical conditions. By expanding their portfolio to include therapies for rare diseases, KORU Medical reaffirms its commitment to meeting the unmet needs of patients worldwide.
The signing of the Phase III clinical supply agreement showcases KORU Medical’s dedication to clinical innovation and becoming a trusted partner in the pharmaceutical industry. With this agreement, the company solidifies its position as a frontrunner in the development and manufacturing of advanced medical technologies.
KORU Medical’s advancements in drug delivery systems hold immense potential for revolutionizing the field of healthcare. By continuously prioritizing patient-centered solutions, the company is spearheading advancements in subcutaneous infusion technology. This progress not only benefits patients, but also healthcare professionals by streamlining treatment administration and improving patient outcomes.
In summary, KORU Medical Systems’ regulatory clearance in Japan for the FreedomEdge System signifies a significant milestone in the company’s mission to provide accessible and patient-centric infusion solutions. The ability to deliver multiple drugs, including CSL Behring’s Hizentra, opens up new possibilities for patients managing their healthcare at home. Furthermore, the Phase III clinical supply agreement for a novel endocrinological therapy expands KORU Medical’s portfolio and solidifies their commitment to addressing unmet medical needs. As the company continues to innovate, its contributions to the medical field are poised to improve the lives of countless patients worldwide.
Comments